CME

Academic Programmes

Ozempic in Contemporary T2D Care: Insights from the Originator Experience – The Ozempic Exchange

10 September, 2026

Academic Programmes

Contemporary Evidence with GLP-1RAs in People Living with MASH – Wegovy 3SP Multispecialty Meeting

20 August, 2026

Academic Programmes

Pharmacotherapy of POCS with reference to obesity – CME by Novo

5 July, 2026

Academic Programmes

Advancing Diabetes Management with Connected CGM – CME by Abbott India

14 August, 2026

Academic Programmes

One Choice, Multiple Wins: Semaglutide as First-Line Therapy in T2D – CME by Novo

30 June, 2026

Academic Programmes

AWIQLI Medical Briefing – CME by Novo Nordisk

2 August, 2026

Academic Programmes

Beyond GLP-1 RAs: Mounjaro – A Class of Its Own – CME by Lilly

29 June, 2026

Academic Programmes

From Base to Peak: Approaching the Obesity Mountain with Tirzepatide – CME by Cipla

27 June, 2026

Academic Programmes

Evolving Metabolic Outcome with Semaglutide – What a Clinician Should Know in 2026 – CME by Alkem

1 August, 2026

Academic Programmes

From Glycemic Challenges to Practical Solutions – CME by Eris

26 June, 2026

Academic Programmes

Innovator Semaglutide: Translating Cardiometabolic Evidence into Practice – Wegovy 3SP Multispecialty Meeting

25 July, 2026

Academic Programmes

Innovator Semaglutide 2.4 mg: A Benchmark Therapy for Chronic Weight Management – CME by Novo (Wegovy)

23 June, 2026